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Impact of Patching and Atropine Treatment 
on the Child and Family 
in the Amblyopia Treatment Study 
Pediatric Eye Disease Investigator Group* 
Obiective: To assess the psychosocial impact on the child 
and family of patching and atropine as treatments for mod-
erate amblyopia in children younger than 7 years. 
Methods:  In a randomized, controlled clinical trial, 419 
children younger than 7 years with amblyopic eye vi-
sual acuity in the range of 20/40 to 20/100 were as-
signed to receive treatment with either patching or at-
ropine at 4 7 clinical sites. After 5 weeks of treatment, a 
parental quality-of-life questionnaire was completed for 
364 (87%) of the 419 patients. 
naire. The overall Amblyopia Treatment Index scores and 
the 3 subscale scores were consistently higher (worse) 
in the patching group compared with the atropine-
treated group (overall mean, 2.52 vs 2.02, P<.001; ad-
verse effects of treatment: mean, 2.35 vs 2.11, P= .002; 
difficulty with compliance: mean, 2.46 vs 1.99, P<.001; 
and social stigma: mean, 3.09 vs 1.84, P < . 0 0 1 ,  
respectively). 
Main Outcome Measure :  Overall and subscale scores 
on the Amblyopia Treatment Index. 
Conclusion: Although the Amblyopia Treatment In-
dex questionnaire results indicated that both atropine 
and patching treatments were well tolerated by the child 
and family, atropine received more favorable scores over-
all and on all 3 questionnaire subscales. 
Results: High internal validity and reliability were dem-
onstrated for the Amblyopia Treatment Index question- Arch Ophthalmol. 2003;121:1625-1632 
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T HE AMBLYOPIA Treatment Study 1 was a randomized, controlled clinical trial de-signed to compare atropine sulfate 1 % eyedrops and eye 
patching (referred to subsequently as 
"patching") as treatments for moderate am-
blyopia (visual acuity 20/40 to 20/100) in 
children younger than 7 years. 1 The re-
sults of the study disclosed that substan-
tial improvement in the visual acuity of the 
amblyopic eye occurred with both the 
patching and the atropine treatment regi-
mens. Improvement was more rapid in the 
patching group, but by 6 months the dif-
ference in visual acuity between groups was 
small (about one third of a line) and clini-
cally inconsequential. 1 
A secondary outcome measure of the 
clinical trial was the results of a question-
naire, the Amblyopia Treatment Index 
(A Tl), that was developed to assess the ac-
ceptability of treatment and its impact on 
the child and family. 2 As such, the ques-
tionnaire might be considered a method 
of assessing some quality-of-life domains 
during treatment for amblyopia. The A Tl 
explores several aspects of the impact of 
treatment for amblyopia in children, in-
cluding parental stress, concern about how 
others may perceive the child, strained 
family relationships, and difficulty with 
treatment adherence. 
In a prior publication,1 we provided 
a brief summary of the ATI questionnaire 
results, which showed that atropine treat-
ment was significantly better accepted than 
patching, although both treatments were 
reported to be generally well tolerated by 
the patient and parent(s). Herein, we pro-
vide further details of these results, as-
sess the relationship of patient character-
istics to A Tl questionnaire responses, and 
report on the internal validity and reli-
ability of the questionnaire. 
METHODS 
STUDY PROTOCOL 
The study protocol has been detailed in prior 
publications1.3 and is summarized below. The 
study was conducted by the Pediatric Eye Dis-
ease Investigator Group at 4 7 clinical sites and 
Table 1. Amblyopia Treatment Index* 
Patching Questionnaire 
1. My child does not seem to mind wearing the patch once it is on. 
2. I worry that by wearing the patch, my child may miss out on fun 
activities (such as games and parties). 
3. Wearing the patch affects my child's learning. 
4. Wearing the patch makes it hard for my child to play outside, 
such as running, jumping, or riding a bike or tricycle. 
5. I have trouble putting on my child's patch and keeping it on. 
6. Wearing the patch is a source of tension or conflict in my 
relationship: 
a. with my child. 
b. with another family member. 
c. with my child's babysitter or teacher. 
7. Wearing the patch makes it difficult for my child to draw, color, or 
write. 
8. I worry that my child will become injured when wearing the patch. 
9. My child can see well when wearing the patch. 
10. My child complains when it is time to wear the patch. 
11. Wearing the patch makes my child's eye or eyelids red or irritated. 
12. I worry that my child does not wear the patch enough. 
13. My child is more clumsy and uncoordinated than usual when 
wearing the patch. 
14. I notice that other children stare at my child when the patch is on. 
15. I believe that wearing the patch will improve my child's vision. 
16. Wearing the patch makes it difficult for my child to play with 
blocks or toys. 
17. I sometimes forget to put the patch on my child. 
18. I worry that wearing the patch will make my child feel different 
from other children. 
Atropine Questionnaire 
1. My child does not seem to mind using the drops. 
2. I worry that by using the drops, my child may miss out on fun 
activities (such as games and parties). 
3. Using the drops affect my child's learning. 
4. Using the drops makes it hard for my child to play outside, such as 
running, jumping, or riding a bike or tricycle. 
5. I have trouble putting the drops in my child's eye. 
6. Using the drops is a source of tension or conflict in my 
relationship: 
a. with my child. 
b. with another family member. 
c. with my child's babysitter or teacher. 
7. Using the drops makes it difficult for my child to draw, color, or 
write. 
8. I worry that my child will become injured when using the drops. 
9. My child can see well when using the drops 
10. My child complains when it is time to put in the drops. 
11. Using the drops makes my child's eye or eyelids red or irritated. 
12. I worry that my child does not get the drops often enough. 
13. My child is more clumsy and uncoordinated than usual when using 
the drops. 
14. I notice that other children stare at my child when the drops are in. 
15. I believe that using the drops will improve my child's vision. 
16. Using the drops makes it difficult to my child to play with blocks or
toys. 
17. I sometimes forget to put the drops in my child's eye. 
18. I worry that using the drops will make my child feel different from 
other children. 
*On the questionnaire, each item has 5 response choices: strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. In addition to the 
5 responses, questions 6b and 6c also had the response choice of "not applicable." 
supported through cooperative agreements with the National 
Eye Institute of the National Institutes of Health, Bethesda, Md. 
The protocol and informed consent forms were approved by 
the participating institutional review boards. The parent or 
guardian (referred to subsequently as "parent") of each study 
patient gave written informed consent. The major eligibility cri-
teria for the trial included the following: being younger than 7 
years and having the ability to complete the study's visual acu-
ity testing protocol4•5 ( which created an effective lower age limit 
of about 3 years old), having a visual acuity in the amblyopic 
eye between 20/40 and 20/100 (inclusive), having an intereye 
visual acuity difference of 3 or more logMAR lines, having or 
having a history of an amblyogenic factor meeting study-
specified criteria for strabismus or anisometropia, and under-
going no more than 2 months of amblyopia treatment in the 
prior 2 years. Each patient was randomly assigned to treat-
ment with either patching (ranging from 6 hours per day to 
full time at investigator discretion) or 1 drop per day of atro-
pine sulfate 1 %. The main outcome measure was visual acuity 
in the amblyopic eye at 6 months, measured using the Ambly-
opia Treatment Study visual acuity testing protocol.4-5 The A TI 
scores were a secondary outcome. 
The A TI questionnaire was completed by the parent who 
accompanied the child to the office at the time of the first fol-
low-up visit, that is, after 5 weeks of treatment (visit time win-
dow, 3-7 weeks). The questionnaire consists of20 Likert-type 
items (Table 1) with 5 response choices ranging from "strongly 
agree" to "strongly disagree," with higher scores (ie, "dis-
agree") indicating more (adverse) impact; a sixth choice of "not 
applicable" was offered for 2 of the questions. At the clinic visit, 
the parent was given brief verbal instructions and then asked 
to complete the ATI questionnaire. The questionnaire was com-
pleted before the child's ophthalmological examination was per-
formed and specifically before the results of visual acuity test-
ing were known. The parent placed the questionnaire in a 
preaddressed postage-paid envelope and sealed it; the enve-
lope was mailed to the study's Central Coordinating Center. If 
the child was not accompanied to the visit by a parent who was 
involved in administering the treatment, a questionnaire was 
not completed for that child. 
STA TIS TI CAL ANALYSIS 
As an initial analysis, the internal validity and reliability of the 
A TI questionnaire were assessed. Broadly defined, validity is 
the property of measuring what one intends to measure. Va-
lidity may be measured externally by correlating question-
naire results to results on preexisting questionnaires that should 
be either positively or negatively associated with the novel ques-
tionnaire. Alternatively, internal validity may be measured by 
examining the factor structure of the novel questionnaire, 
namely, how the individual items on the questionnaire corre-
late with underlying factors. 6•7 Such factors could initially be 
labeled "A," "B," "C," etc, and then, by examining the specific 
items that are highly associated with each factor, they could 
be relabeled as "subscales." In the present case, concepts re-
lated to the treatments, for example, compliance or adher-
ence, were used to name the subscales. Defined in this way, 
high internal validity is the result of a simple factor structure 
with high correlations (eg,  0.5) between individual items and 
the underlying factors. Internal validity is of particular impor-
tance when preexisting questionnaires are scarce. 
Reliability may be viewed as the repeatability of test items 
and is often measured either by the correlation of test-retest 
administrations or by the Cronbach a on a single test admin-
istration.8 A desirably strong reliability (eg,  0.8) suggests that 
Table 2. Amblyopia Treatment Index: Questionnaire Responses by Treatment Group* 
Strongly Neither Agree Strongly Mean 
Agree Agree nor Disagree Disagree Disagree Resp onse† 
Item (Abbreviated) (5) (4) (3) (2) (1) (1-5) 
Patching Group (n = 186) 
7 13 9 47 24 2.31 
2 11 13 51 23 2.19 
2 6 15 50 28 2.04 
1 24 15 44 17 2.49 
6 10 10 46 28 2.21 
6 12 7 43 32 2.16 
2 3 6 45 38 1.80 
1 2 4 44 34 1.74 
2 11 13 54 20 2.22 
0.5 18 12 49 20 2.31 
3 20 27 41 8 2.70 
18 30 14 28 9 3.20 
7 27 16 41 8 2.84 
6 14 13 46 20 2.40 
4 26 18 42 10 2.71 
15 49 17 17 3 3.56 
1 0.5 5 52 42 1.68 
1 6 14 59 20 2.10 
2 22 6 36 33 2.24 
1. Child does not seem to mind treatment‡ 
2. Worry child may miss out on fun activities 
3. Treatment affects child's learning 
4. Treatment makes it hard for child to play 
5. Trouble applying treatment to child 
6. Treatment is a source of tension for me 
a. with child 
b. with another family member§ 
c. with my child's babysitter or teacher§ 
7. Difficult for child to draw, color, or write 
8. Worry child will be injured on treatment 
9. My child can see well while on treatment‡ 
10. Child complains when it is time for treatment 
11. Child's eye or eyelids become red or irritated 
12. Worry that child not getting enough treatment 
13. Child clumsy on treatment 
14. Other children stare at child 
15. Treatment will improve child's vision‡ 
16. Treatment makes it difficult for child to play 
17. Sometimes forget to apply treatment to child 
18. Worry that child feels different 8 28 19 33 12 2.87 
Atropine Group (n = 178) 
8 10 7 38 38 2.13 
1 10 7 43 39 1.90 
2 11 18 39 31 2.14 
3 7 8 48 34 1.97 
4 9 6 39 42 1.93 
2 4 6 41 47 1.73 
2 2 35 52 1.49 
0.6 1 34 43 1.48 
2 12 11 42 34 2.07 
2 12 11 40 35 2.04 
3 24 28 35 10 2.76 
7 21 11 33 28 2.46 
0.6 6 7 45 42 1.78 
0.6 3 8 44 45 1.70 
0.6 19 10 41 29 2.20 
1 6 6 41 46 1.76 
2 16 48 34 1.86 
0.6 3 13 43 40 1.80 
1 17 7 34 41 2.04 
1. Child does not seem to mind treatment‡ 
2. Worry child may miss out on fun activities 
3. Treatment affects child's learning 
4. Treatment makes it hard for child to play 
5. Trouble applying treatment to child 
6. Treatment is a source of tension for me 
a. with child 
b. with another family member§ 
c. with my child's babysitter or teacher§ 
7. Difficult for child to draw, color, or write 
8. Worry child will be injured on treatment 
9. My child can see well while on treatment‡ 
10. Child complains when it is time for treatment 
11. Child's eye or eyelids become red or irritated 
12. Worry that child not getting enough treatment 
13. Child clumsy on treatment 
14. Other children stare at child 
15. Treatment will improve child's vision‡ 
16. Treatment makes it difficult for child to play 
17. Sometimes forget to apply treatment to child 
18. Worry that child feels different 3 10 7 41 38 1.98 
*Data are given as percentages unless otherwise indicated. 
†The average of all responses excluding "not applicable" responses on a 5-point Liker! scale. 
:j:Data for questions 1, 9, and 15 have been reversed so that a higher score implies a negative connotation. 
§"Not applicable" responses for 6b and 6c (see Table 1) were as follows: 6b, 7% in the patching group and 9% in the atropine group; 6c, 15% in the patching 
group and 22% in the atropine group. 
subjects given the questionnaire on 2 different occasions (close 
enough in time such that the underlying process being mea-
sured has not changed) would score similarly. 
Frequency tables were used to describe the item-response 
distributions and to assess whether any items had limited range. 
Factor analy sis was conducted combining patients from both treat-
ment groups. Responses for 22 patients missing 1 item were im-
puted based on an average response across all completed ques-
tions for that child. Questions 6b and 6c did not apply to all 
respondents and were not included in the factor analysis, leav-
ing 18 items for inclusion in the factor analysis. Any factor with 
an eigenvalue ( the amount of combined item variance accounted 
for by the factor) greater than 1 was retained for interpretation. 7 
Item loadings, an estimate of the correlation between the item and 
the underlying factor, that rounded to 0.5 or greater were con-
sidered noteworthy. 7 To simplify the factor structure, items that 
(1) did not load strongly on any factor, (2) loaded on several fac-
tors equally, or (3) whose removal notably increased the inter-
nal consistency reliability were not included in the final explor-
atory factor analysis nor included in subscales. A subscale name 
was defined for each factor by examining the theme of items that 
loaded strongly on that factor. The numerical value of each sub-
scale was calculated as the mean of the individual items compos-
ing the subscale. Therefore, subscale scores took values from 1
to 5, with higher values indicating higher agreement. Internal-
consistency reliability for the subscales was estimated by the Cron-
Table 3. Correlation Between Items and Factors From Factor Analysis of 364 Respondents 
Type of Subscale 
Adverse Effects Lack of Treatment Social 
Factor Loadings for Retained Items* of Treatment Compliance Stigma 
Items composing the adverse effects of treatment subscale 
2. Worry that child on treatment may miss out on fun activities 0.5 0.1 0.4 
3. Treatment affects child's learning 0.7 0.1 0.0 
4. Treatment makes it hard for child to play outside 0.6 0.2 0.4 
0.7 0.2 0.1 
0.5 0.1 0.4 
7. Difficult for my child to draw, color, or write 
8. Worry that child on treatment will become injured 
9. Child can see well on treatment† 0.6 0.2 0.1 
13. Child clumsy on treatment 0.6 0.1 0.4 
16. Treatment makes it difficult for child to play 0.6 0.2 0.3 
Items composing the lack of treatment compliance subscale 
0.2 0.8 0.1 
0.2 0.7 0.1 
1. Child does not seem to mind treatment†
5. Trouble applying treatment to child 
6a. Treatment is a source of tension or conflict with child 0.3 0.7 0.2 
10. Child complains when it is time for treatment 0.1 0.7 0.3 
12. Worry child not getting enough treatment 0.1 0.5 0.3 
Items composing the social stigma subscale 
11. Treatment makes my child's eye or eyelids red or irritated 0.2 0.3 0.5 
14. Other children stare at child 0.0 0.1 0.8 
18. Worry that child feels different 0.3 0.2 0.7 
*Estimated factor loadings greater than 0.5 are in boldfaced type. Items 15 and 17 did not load strongly (r<0.5) on any single factor and are not listed. 
Questions 6b and 6c (see Table 1) did not apply to all of the respondents and were not included in the factor analysis. 
†For ease of interpretation, data for this question have been reversed so that a higher score implies a negative connotation. 
bach a.8 There were no obvious differences in the creation of sub-
scales or subscale reliabilities when the analyses were conducted 
stratified by treatment group (data not shown). For each pa-
tient, an overall score was computed as a weighted average of the 
3 subscale scores ( weighted based on the number of items in the 
subscale). 
Treatment group differences for the overall ATI question-
naire score and subscale scores were assessed with independent 
sample t tests. Interaction between baseline factors (age, visual 
acuity of the amblyopic eye, cause of amblyopia, and a history of 
amblyopia treatment) and treatment group on the A Tl question-
naire score was assessed by including interaction terms in linear 
regression models. Within each treatment group, the associa-
tions between patient factors and the overall ATI questionnaire 
scores were evaluated using linear regression, with the question-
naire score as the dependent variable and the patient factor as the 
independent variable (all factors were analyzed as continuous vari-
ables except for prior treatment and cause of amblyopia which 
were analyzed as categorical variables). All reported P values are 
2-sided. Statistical analyses were performed using SAS statistical 
software (PC Version 8.01; SAS Institute Inc, Cary, NC). 
RESULTS 
The ATI questionnaires were completed for 364 (87%) 
of the 419 patients enrolled in the Amblyopia Treatment 
Study 1: for 186 (87%) of 215 patients in the patching 
group and for 178 (87%) of 204 patients in the atropine 
group. Eleven patients missed the 5-week visit at which 
the A Tl questionnaire was to be completed, 4 patients 
were not accompanied to the visit by a parent or guard-
ian involved in administering the treatment, and 12 
patients were enrolled at a site that did not have institu-
tional review board approval for the completion of the 
questionnaire. Among the other 28 patients for whom a 
questionnaire was not completed, for 5 patients the site 
personnel neglected to distribute the questionnaire, for 
13 patients a questionnaire was distributed but was not 
returned, and for 10 patients the reason for noncomple-
tion was not documented. There were no meaningful 
differences comparing the demographic and clinical 
characteristics of the 55 patients for whom a question-
naire was not completed with those of the 364 patients 
for whom a questionnaire was completed (data not 
shown). 
The 364 patients for whom questionnaires were com-
pleted had a mean age of 5.2 years; 46% were female. 
Ninety-four patients (26%) had been treated previously 
for amblyopia, most often (86 patients [91 %]) with patch-
ing. The mean baseline visual acuity in the amblyopic eye 
was approximately 20/60. These characteristics are simi-
lar to those reported for the full study cohort (N =419). 1 
The mother was the respondent for 281 patients 
(77%), the father for 69 patients (19%), and another in-
dividual for 14 patients ( 4%). Fifty percent of the re-
spondents indicated that they were the individual who 
was responsible for the treatment all of the time and an 
additional 32% indicated that they were responsible for 
the treatment most of the time. 
INTERNAL VALIDITY AND RELIABILITY 
OF THE ATI QUESTIONNAIRE 
Missing responses on the questionnaire items were mini-
mal. Only 22 ( < 1 %) of 6552 possible item-responses were 
missing by 22 different respondents. Seventeen of the 18 
items demonstrated adequate variability as evidenced by 
the frequency distributions for item-responses (Table 2).  
One item (No. 15 ["I believe that treatment will im-
prove my child's vision."]) was limited in the response 
range with 94% of the responses clustered in the strongly 
agree or agree category. 
In a factor analysis, 16 of the 18 items were corre-
lated strongly (2:::0.5) with 1 of3 underlying factors hav-
ing an eigenvalue greater than 1 (Table 3).  A 3-factor 
solution was also suggested by visual inspection of a scree 
plot. The 3 factors remained after an iterative process of 
removing items that did not load strongly on any factor 
(items 15 and 17). These 3 factors were then defined as 
subscales on the basis of the items that were highly as-
sociated with each factor: (1) adverse effects of treat-
ment ( 8 items), (2) difficulties with compliance (5 items), 
and (3) social stigma of the treatment (3 items). The in-
ternal-consistency reliability of the 8-item adverse ef-
fects subscale was 0.86, the 5-item compliance subscale 
reliability was 0.86, and the 3-item social stigma sub-
scale reliability was 0. 75. The internal-consistency reli-
ability for the 16-item overall scale was 0.89. 
TREATMENT GROUP COMPARISON 
The distribution of responses for each ATI question-
naire item is provided by treatment group in Table 2. The 
mean overall scale score was 2.52 in the patching group 
and 2.02 in the atropine group, indicating that overall 
both treatments were perceived to be well tolerated on 
the 5-point Likert scale (P<.001 favoring the atropine 
group). The questionnaire scores were consistently higher 
(worse) on all 3 subscales in the patching group com-
pared with the atropine group (adverse effects: mean, 2.35 
vs 2.11, P= .002; difficulty with compliance: mean, 2.46 
vs 1.99, P<.001; and social stigma: mean, 3.09 vs 1.84, 
P<.001, respectively [Table 4]).  There was no statis-
tically significant interaction between baseline factors 
and treatment group on the overall questionnaire scores 
(P values for interaction= .56 for age, .38 for baseline am-
blyopic eye visual acuity, .82 for cause of amblyopia, and 
.20 for a history of amblyopia treatment). 
ASSOCIATION OF BASELINE 
AND PATIENT FACTORS 
AND A TI QUESTIONNAIRE RESPONSES 
Within each treatment group, the association of baseline 
factors with the questionnaire responses was assessed. In 
each treatment group, there was no significant associa-
tion between the overall questionnaire scores and age, base-
line amblyopic eye visual acuity, or cause of amblyopia 
(Table 5). In the atropine group, patients with a history 
of amblyopia treatment (almost always prior patching treat-
ment) had higher (worse) scores than did patients with 
no history of treatment (P=.01). On evaluating the sub-
scale scores between those with and without a history of 
treatment, this association was seen to be primarily be-
cause of the differences in scores on the adverse effects sub-
scale. This association between a history of amblyopia treat-
ment and the A TI questionnaire scores was not found in 
the patching group (P= .53). 
Patients prescribed 10 or more hours per day of 
patching had similar overall A TI questionnaire scores com-
pared with patients prescribed 6 to 8 hours per day (mean 
scores, 2.61 and 2.49, respectively, P=.15). In analyz-
Table 4. The Amblyopia Treatment Index Subscale Scores 
According to Treatment Group* 
Patching Atropine 
Group 
Average Score† (n = 186) 
Group p 
(n = 178) Value‡ 
Overall 
1 (strongly disagree) 0 3 (2) 
>1-2 36 (19) 91 (51) 
>2-3 116 (62) 72 (40) 
>3-4 29 (16) 12 (7) 
>4-5 5 (3) 0 
Mean (SD) 2.52 (0.63) 2.02 (0.63) <.001 
Difference§ (95% Cl) 0.50 (0.37-0.63) 
Median (interquartile 2.47 (2.13, 2.87) 2.00 (1.50, 2.44) 
range) 
Adverse effects of 
treatment subscale 
1 (strongly disagree) 3 (2) 10 (6) 
>1-2 63 (34) 85 (48) 
>2-3 95 (51) 64 (36) 
>3-4 21 (11) 18 (10) 
>4-5 4 (2) 1 (0.6) 
Mean (SD) 2.35 (0.69) 2.11 (0.72) .002 
Difference§ (95% Cl) 0.23 (0.09-0.38) 
Median (interquartile 2.25 (1.88, 2.75) 2.00 (1.50, 2.63) 
range) 
Lack of treatment 
compliance subscale 
1 (strongly disagree) 5 (3) 29 (16) 
>1-2 75 (40) 86 (48) 
>2-3 63 (34) 42 (24) 
>3-4 28 (15) 17 (10) 
>4-5 15 (8) 4 (2) 
Mean (SD) 2.46 (0.96) 1.99 (0.83) <.001 
Difference§ (95% Cl) 0.47 (0.28-0.65) 
Median (interquartile 2.20 (1.80, 3.00) 1.80 (1.40, 2.60) 
range) 
Social stigma subscale 
1 (strongly disagree) 4 (2) 50 (28) 
>1-2 23 (12) 83 (47) 
>2-3 69 (37) 32 (18) 
>3-4 73 (39) 12 (7) 
>4-5 17 (9) 1 (0.6) 
Mean (SD) 3.09 (0.81) 1.84 (0.74) <.001 
Difference§ (95% Cl) 1.25 (1.10-1.41) 
Median (interquartile 3.00 (2.67, 3.67) 2.00 (1.00, 2.33) 
range) 
Abbreviation: Cl, confidence interval. 
*Data are given as the number (percentage) of respondents unless otherwise 
indicated. 
†A  higher score is worse. 
‡Pvalue for difference in mean from t test. 
§Positive difference indicates atropine-treated group is better. 
ing the subscale scores, there was a suggestion of higher 
scores on the social stigma subscale but not on the other 
2 subscales for the patients prescribed the greater num-
ber of patching hours (mean scores, 3.25 and 3.04, re-
spectively,
In a randomized, controlled clinical trial of patching vs 
atropine treatment for moderate amblyopia, we used the 
A TI questionnaire to assess the impact of treatment on 
the child and family. In both treatment groups, the ATI 
Table 5. Association of Patient Factors and Overall Amblyopia Treatment Index Questionnaire Scores 
Patching Group Atropine Group 
No. of Mean Overall P Value No. of Mean Overall P Value 
Factor Children Score Within Group* Children Score Within Group* 
Age, y 
< 4  33 30 1 . 9 6 
4-<5 37 2.51 .18 36 2.00 .67 5-<6 56 2.63 65 2.05 
6-<7 60 2.53 47 2.04 
Baseline amblyopic eye visual acuity† 
20/40 18 247 23 1 . 8 4
20/50 41 2.55 35 1.94 
20/60 47 2.50 .75 28 2.19 .15 
20/80 37 2.46 50 1.98 
20/100 43 2.58 41 2.11 
Cause of amblyopia‡ 
Strabismus 71 2 . 5 3 69 2 . 0 7 ]  
Anisometropia 75 2.48 .66 66 1.93 .35 
Strabismus and anisometropia 39 2.59 39 2.06 
Prior amblyopia treatment§ 
Yes 44 2.57 .53 50 2.21 .01 No 142 2.50 128 1.95 
Improvement from baseline to 5 wk in 
amblyopic eye visual acuity, No. of lines 
49 2 . 7 4 ]  88 2 . 0 5 ]  
62 2.45 .09 57 1.96 .50 
< 2  
2 
≥3 75 2.44 33 2.04 
* P value for the association between the factor and the overall score within treatment group from linear regression with the overall score as the dependent 
variable and the patient factor as the independent variable (all factors were analyzed as continuous variables except for prior treatment and cause of amblyopia, 
which were analyzed as categorical variables). 
†one patient in the atropine group with a baseline amblyopic eye visual acuity of 20/125 was not included. 
‡Five patients (1 in the patching group and 4 in the atropine group) with indeterminate cause for amblyopia were not included. 
§For 91 % of the patients who received prior amblyopic treatment, patching was the prior treatment. 
questionnaire results indicated that the initial month of 
treatment was usually well tolerated by the child and par-
ent. Atropine was a more acceptable treatment than patch-
ing overall and on 3 A TI subscales of adverse effects, treat-
ment compliance, and social stigma. However, the 
absolute differences between the atropine-treated and 
patching groups were small (about half of a unit on the 
1 to 5 scale). 
Although questionnaires, such as the Parenting Stress 
Index,9 have been developed for assessing quality of life 
in children and their families in a variety of pediatric con-
ditions, 1 0•1 1 there is a lack of published data on the qual-
ity of life during amblyopia treatment and the impact of 
treatment on the child and family. Searle et al12 qualita-
tively assessed psychosocial effects of patching in paren-
tal interviews of 20 families with a child aged 2 to 7 years 
who was prescribed 2 to 7 hours per day of patching. The 
authors reported that many parents experienced dis-
tress related to patching. However, no quantification was 
provided either for the proportion of parents reporting 
distress or for the degree of distress. Thus, a meaningful 
comparison with our results cannot be made. News-
ham 13 used a parental questionnaire to assess reasons for 
noncompliance in 31 children aged 2 to 7 years with poor 
patching compliance. He reported that the most com-
mon reason in 45% of cases was the parental decision to 
defer treatment until the child was older and presum-
ably more cooperative. 
Atropine treatment has been previously reported in 
several uncontrolled case series to have an excellent level 
of acceptability by patients and parents. 14-16 Comparing 
patching with atropine treatment in a prospective study 
of 36 children aged 2 to 9 years old, Foley-Nolan et al17 
reported superior acceptability and compliance with at-
ropine treatment. Data from our randomized, con-
trolled clinical trial using the A TI questionnaire sup-
port this finding of higher acceptability for atropine 
treatment, providing at least one rationale for the use of 
the atropine treatment in preference to patching. Al-
though we found that patching was associated with worse 
ATI scores than the atropine treatment, the results indi-
cated that patching generally was well tolerated, and the 
scores of the patching group were better than might have 
been anticipated based on our clinical experience. 
The age of the patient, depth of amblyopia, and cause 
of amblyopia showed little relationship with the overall 
ATI questionnaire score. Within the patching group, the 
scores were similar in children who had been previ-
ously treated for amblyopia and those who had not. Within 
the atropine group, previously treated children (mostly 
treated with patching) had higher (worse) scores, on av-
erage, than did children who were being treated for the 
first time. However, the previously treated children in the 
atropine group still had lower (better) scores than did 
the previously treated children in the patching group. In 
view of the multiple statistical associations that were 
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Clinical Sites 
Listed in order of number of patients enrolled into the Amblyopia Treatment Study 1, with city, state, site name, and number of patients in paren-
theses. Personnel are listed as (I) for investigator, (C) for coordinator, and (V) for visual acuity tester. 
Gaithersburg, Md (36): Stephen R. Glaser (I), Andrea M. Matazinski (C), David M. Sclar (V). Erie, Pa; Pediatric Ophthalmology of Erie (33): 
Nicholas A. Sala (I), Chrissy M. Vroman (C), Cindy E. Tanner (V). Dallas, Tex; Pediatric Ophthalmology PA and the Center for Adult Stra-
bismus (26): David R. Stager, Sr (I), Priscilla M. Berry (I), David R. Stager,Jr (I),Joost Felius (C),Jennifer A. Wilkerson (C), Maria Petrova 
Pesheva (C), Eileen E. Birch (V); Brett G. Jeffrey (V), Anna R. O'Connor (V). Providence, RI; Pediatric Ophthalmology and Strabismus Asso-
ciates (25): David Robbins Tien (I), Glenn E. Bulan (I), Heidi C. Christ (C), Lauren B. DeWaele (C), David A. Young (V). Calgary, Alberta 
Children's Hospital (24): William F. Astle (I), Anna L. Ells (I), Cheryl R. Hayduk (C), Catriona I. Kerr (C), Mary S. McAlester (C), Heather 
J. Peddie (C), Heather M. Vibert (C). Bethesda, Md; National Eye Institute (20): Richard W. Hertle (I), Susan D. Mellow (C), Ed]. Fitzgibbon 
(V), Guy E. Foster (V). Anchorage, Alaska; Ophthalmic Associates (20): Robert W. Arnold (I), Mary Diane Armitage (C), Nancy H. Brusseau 
(V). Milwaukee; Medical College of Wisconsin (18): Mark S. Ruttum (!),Jane D. Kivlin (I), Veronica R. Picard (C), Merelynj. Chesner (V). 
Fullerton; Southern California Colfege of  Optometry (17): Susan A. Cotter (I), Carmen N. Barnhardt (I), Susan M. Shin (I), Raymond H. Chu 
(I), Lourdes Asiain (C), Yvonne F. Flores (C), Gen Lee (C),John H. Lee (V), Sherene C. Fort (V),Jennifer L. Slutsky (V). Houston; Texas 
Children's Hospital (14): Evelyn A. Paysse (I), David K. Coats (I), Kathr y n  M. Brady-Mccreery (I), Alma D. Sanchez (C), Viviana Correodor 
(C). Nashville, Tenn; Vanderbilt Eye Center (13): Sean Donahue (I), Cindy Foss (C),Julie A. Ozier (C), Ronald]. Biernacki (V), Evelyn 
Tomlinson (V). Portland, Ore; Casey Eye Institute (12): David T. Wheeler (I), Kimberley A. Beaudet (C), Christin L. Bateman (V), Michele 
A. Hartwell (V). Sacramento, Calif; The Pennanente Medical Group (11):James B. Ruben (I), Dipti Desai (C), Sue Ann Parrish (C), Tracy D. 
Louie (V). University of Alabama at Binningham School of  Optometry (10): Robert P. Rutstein (I), Wendy L. Marsh-Tootle (I), Cathy H. Bald-
win (C), Kristine T. Becker (V). Baltimore, Md; Wilmer Institute (10): Michael X. Repka (I), David G. Hunter (!),Jana Mattheu (C), Sheena 
0 .  Broome (V), Carole R. Goodman (V). Indianapolis; Indiana University Medical Center (9): Daniel E. Neely (I), David A. Plager (I), Derek 
T. Sprunger (I), Donna]. Bates (C),Jay Galli (C), Michele E. Whitaker (C). Fort Lauderdale, Fla; NOVA Southeastern University (9): Susanna 
M. Tamkins (I), Michele Gonzalez (C), Siby Jacobs (V). Baltimore, Md; Greater Baltimore Medical Center (7): Mary Louise Z. Collins (I), 
Cheryl L. McCarus (C),Jaime N. Brown (V), DorothyB. Conlan (V). Atlanta, Ga; Emory Eye Center (7): Scott R. l.ambert (I), Lucy Yang (C), 
Alexander T. Elliott (C), Nicole Fallaha (V). St Louis, Mo; Cardinal Glennon Children's Hospital (6): Oscar A. Cruz (I), Bradley V. Davitt (I), 
Susan A. Havertape (C), Emily A. Miyazaki (C), Molly B. Bosch (C). Waterbury, Conn; Ophthalmic Surgical Associates (6): Andrew J. Levada 
(I), Tabitha L. Matchett (C), Angela Zimmerman Moya (C), Cara C. Mulligan (V), Holly J. Pelletier (V), Shelley K. Weiss (V). Grand Rapids, 
Mich; Pediatric Ophthalmology PC (6): Patrick]. Droste (I), Robert]. Peters (I),Jan Hilbrands (C), Kelli A. Sheeran (V), Deborah K. Smith 
(V), Corrie L.Vanrazenswaay (V). Dallas; University of  Texas Southwestern Medical Center (6): David R. Weakley,Jr (I), Clare L. Dias (C). 
Wichita, Kan; Grene Vision Group (5): David A. Johnson (I), Ruth D. James (C), Patti G. Claes (V), Kellie K. Drake (V). Rochester, Minn; 
Mayo Clinic (5):Jonathan M. Holmes (I), Becky A. Nielsen (C), Marcela Garcia (V), Rose M. Kroening (V), David A. Leske (V), Marna L. 
Levisen (V), Deborah K. Miller (V), Debbie M. Priebe (V), Julie A. Spitzer (V). Philadelphia; Pennsylvania College of  Optometry (5): Mitchell 
M. Scheiman (!),Jo Ann T. Bailey (I), Kathleen T. Zinzer (V). Columbus; Ohio State University College of Optometry (5): Marjean T. Kulp (I), 
Tracy L. Kitts (C), Michael]. Earley (V). Buffalo, NY; Children's Hospital o f  Buffalo (4): StevenAwner (I), Scott E. Olitsky (V). Lancaster, Pa; 
Family Eye Group/Eye Specialists oJ Lancaster (4): David I. Silbert (I), Abbe E. Wagner (C), Kit M. Castillo (V), Noelle S. Matta (V), Tracy L. 
Meshey (V), Paulette Myers-Ely (V), Wendy L. Piper (V), Dena M. Scaringi (V), Pamela M. Snavely (V), Lori]. Walker (V). Palm Harbor, 
Fla; Specialty Eye Care ( 4): Christine L. Burns (I), Magda Barsoum-Homsy (1), Le Ila C. Lawrence (C). Chapel Hill; University of  North Caro-
lina, Department of  Ophthalmology (4): David K. Wallace (I), Marguerite]. Sullivan (C). Tucson; University of  Arizona (4):Joseph M. Miller 
(I), Toby Ann Aparisi ( C), Jenniffer Funk-Weyant ( C), Megan Taylor (V), Sue Bulau (V). Iowa City; University of  Iowa Hospitals and Clinics 
(4): William E. Scott (I), Wanda I. Ottar-Pfeifer (C), Pamela]. Kutschke (V), Keith M. Wilken (V). Minneapolis; University of Minnesota (4): 
C. Gail Summers (I), Stephen P. Christiansen (I), Ann M. Holleschau (C), Sally M. Cook (C), Jane D. Lavoie (V), Kim S. Merrill (V). 
Binningham; Alabama Ophthalmology Associates PC (3): Frederick]. Elsas (I), Thomas H. Metz,Jr (I), Michelle L. Mizell (C), Stephanie 0 .
Roberts Bennett (V). Noifolk; Eastern Virginia Medical School (3): Earl R. Crouch,Jr (I), Kristen D. Ruark (C), Gaylord G. Ventura (V). 
Mexico City, Mexico (3): Miguel Paciuc (I), Marina M. Schnadower (C), Cecilio Velasco (V). Temple, Tex; Scott and White Ophthalmology (3): 
David C. Dries (I), V. Jeanne Vengco (C). Salt Lake City; University of Utah/Moran Eye Center (3): Richard]. Olson (I), Robert 0 .  Hoffman 
(I), Susan F. Bracken (C), Pat L. Remington (V), Kimberly G. Yen (V). Asheville, NC; Asheville Eye Associates (2): Robert E. Wiggins,Jr (I), 
Sally A. Baumgartner (C), Mary Knecht (V). Cincinnati, Ohio; Children's Hospital Medical Center (2): Constance E. West (I), Shelley L. 
Benson (C), Laurie A. Hahn-Parrott (V), Walker W. Motley (V), Regina M. Poole (V). Philadelphia; Children's Hospital of Philadelphia (2): 
Brian]. Forbes (I); Graham E. Quinn (I); Melissa L. Ehnbom (V); Michelle C. Maturo (V); David R. Phillips (V). Washington, DC; Children's 
National Medical Center (1): Marijean Michele Miller (I), Mitra Maybodi (I), Cori Greger (C). Canton; Eye Centers of  Ohio (1): Elbert H. 
Magoon (I), Paula A. Kannam (C), Lynn A. McAtee (C), Margie Andrews (V), Caroline M. Hoge (V). Charleston; Medical University of  South 
Carolina, Stonn Eye Institute (1): Richard A. Saunders (!),Judy P. Hoxie (C), Lisa M. Langdale (C), Kimberly D. Lenhart (V). Boston, Mass; 
New England College of Optometry (1): Bruce Moore (I), Erik M. Weissberg (I). New York; State University of New York, College of Optometry 
(1): Robert H. Duc1anan (I), David E. FitzGerald (I), Marilyn Vricella (V). 
Data Coordinating Center 
Tampa, Fla: Roy W. Beck, Pamela S. Moke, R. Clifford Blair, Stephen R. Cole, Raymond T. Kraker, Heidi A. Gillespie, Nicole M. Boyle, Alisha N. 
Lawson, Julie A. Gillett, Shelly T. Mares, Brian B. Dale. 
National Eye Institute 
Bethesda: Donald F. Everett. 
Pediatric Eye Disease Investigator Group Executive Committee 
Michael X. Repka (chair),Jonathan M. Holmes (vice-chair), Roy W. Beck, Eileen E. Birch, Donald F. Everett, Pamela S. Moke. 
Arnblyopia Treatment Study Steering Committee 
Michael X. Repka, RoyW. Beck, Eileen E. Birch, Donald F. Everett, Richard W. Hertle.Jonathan M. Holmes,Joseph M. Miller (1998-2000), Pamela 
S. Moke, Graham E. Quinn (1998-2000), Richard A. Saunders (1998-2000), Kurt Simons (1998-2000), Susan A. Cotter (2000-current), Mitchell 
M. Scheiman (2000-present). 
Arnblyopia Treatment Study 1 Publications Subcommittee 
Joseph M. Miller, Graham E. Quinn, Richard A. Saunders. 
Arnblyopia Treatment Study 1 Operations Subcommittee 
Susan A. Cotter (2000), Stephen R. Glaser, Maria P. Pesheva (2000), Veronica R. Picard (2000-present), Nicholas A. Sala, D. Robbins Tien (2000-present). 
Data and Safety Monitoring Committee 
William Barlow (chair), Edward G. Buckley, Barry Davis, Velma Dobson,John L. Keltner, Hana Osman, Earl A. Palmer, Dale L. Phelps. 
assessed, we think that the association between prior treat-
ment and the A TI questionnaire scores in the atropine 
group was likely related to chance. 
We believe that ourresults are not biased by the knowl-
edge of response to treatment because the A TI question-
naire was completed prior to testing of visual acuity at the 
first follow-up visit. If the visual acuity results were known 
or suspected by the parent, this might bias in favor of the 
patching group since, as we have reported, after 5 weeks 
of treatment there was greater improvement in visual acu-
ity in the patching group than in the atropine group. 1 Since 
the ATI questionnaire was completed only at 5 weeks, we 
do not know whether the better acceptance of atropine than 
patching would have been sustained over several months 
of treatment. 
Regarding the internal validity and reliability of the 
ATI questionnaire, our present data from 364 children 
enrolled in the Amblyopia Treatment Study 1 confirm 
the findings of our original report using data from the 
first 64 patients. 2 We found 3 factors that could be ap-
propriately labeled as the same 3 subscales of (1) ad-
verse effects, (2) treatment compliance, and (3) social 
stigma. Increasing the sample size in the present study 
resulted in finding additional ATI questionnaire items that 
loaded with each factor or subscale, such that 16 of the 
possible 18 items could be used in the subscales, in con-
trast to 11 in the original report of the same question-
naire. In our initial pilot study, we commented2 that the 
social stigma subscale was somewhat weak because it was 
based on only 2 items. Increasing the sample size for the 
current analysis has identified a third questionnaire item 
that loads strongly with this factor likely increasing the 
stability of the social stigma subscale. 
Regarding generalizability, the A TI questionnaire was 
developed specifically for use in the age group of 3- to 
6-year-olds and our results should not be applied to older
or younger children. Patients in the randomized, con-
trolled clinical trial had moderate amblyopia and the re-
sults might differ with severe amblyopia (we are using
the ATI questionnaire to assess quality of life in patch-
ing treatment of severe amblyopia). Our patient popu-
lation was preponderantly white and it is possible that
children and their families of different races might re-
spond differently to patching and/or atropine treat-
ment. As with any clinical trial, patients (parents) who
agree to participate may differ from the general popula-
tion in ways that could influence the results.
w e  used the ATI questionnaire to measure the impact 
of patching and atropine treatments on some quality-of-
life domains in a randomized, controlled clinical trial of 
patching vs atropine treatment for amblyopia. Overall, 
the atropine treatment was better tolerated than patch-
ing. However, the scores for both the atropine treat-
ment and patching were on the whole positive and dem-
onstrated good acceptance of both treatments by the 
children and their parents. 
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